Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study.

Takahashi N, Kim DW, Kim I, Du X, Lee SE, Hu Y, Kikushige Y, Jiang Q, Wang Y, Chen S, Zhu H, Goto T, Tomita A, Ichii M, Nakamae H, Liu L, Liu B, Malek K, Zhu T, Wu S, Wang J

Open source

DOI: 10.1002/cam4.72019
Published: 2026 Jun
Container: Cancer medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cam4.72019,
  title = {Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study.},
  author = {Takahashi N and Kim DW and Kim I and Du X and Lee SE and Hu Y and Kikushige Y and Jiang Q and Wang Y and Chen S and Zhu H and Goto T and Tomita A and Ichii M and Nakamae H and Liu L and Liu B and Malek K and Zhu T and Wu S and Wang J},
  year = {2026},
  journal = {Cancer medicine},
  doi = {10.1002/cam4.72019},
  url = {https://doi.org/10.1002/cam4.72019}
}

RIS

TY  - JOUR
TI  - Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study.
AU  - Takahashi N
AU  - Kim DW
AU  - Kim I
AU  - Du X
AU  - Lee SE
AU  - Hu Y
AU  - Kikushige Y
AU  - Jiang Q
AU  - Wang Y
AU  - Chen S
AU  - Zhu H
AU  - Goto T
AU  - Tomita A
AU  - Ichii M
AU  - Nakamae H
AU  - Liu L
AU  - Liu B
AU  - Malek K
AU  - Zhu T
AU  - Wu S
AU  - Wang J
PY  - 2026
JO  - Cancer medicine
DO  - 10.1002/cam4.72019
UR  - https://doi.org/10.1002/cam4.72019
ER  -

APA

N, T., DW, K., I, K., X, D., SE, L., Y, H., Y, K., Q, J., Y, W., S, C., H, Z., T, G., A, T., M, I., H, N., L, L., B, L., K, M., T, Z., S, W., & J, W. (2026). Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study.. Cancer medicine. https://doi.org/10.1002/cam4.72019

Source records

pubmed · retrieved 2026-09-25T23:37:24.082Z